The primary focus is on emerging biotechnology, pharmaceutical, medical devices, and other innovative technologies and services. The strategy will use individual stock of smaller emerging companies but may also invest in larger companies opportunistically. The strategy may also use ETFs as well.
PVG’s Emerging Healthcare Strategy seeks to outperform the Nasdaq Biotech Index (NBI). Over the long-term, it is expected that the strategy will significantly outperform the S&P 500. The primary focus of the strategy is investing in emerging companies that may not have revenues and may be funding clinical trials in anticipation of the development of a new drug or device.
To manage risk in the strategy cash can be a significant percentage of the portfolio if opportunities do not exist or as individual positions are being changed. Inverse ETFs may be used during uncertain market conditions or to protect significant gains.
PVG is not a market timer.
